Unmasking Brugada Syndrome With Oral Propafenone in a Resource-Limited Setting: A Case Report.
Access-site strategy is the next place TAVR outcomes get refined, and a 600-patient trial is now locked.
The Freiburg-Bad Krozingen group's radial versus femoral secondary access study moved to active, not recruiting.
Brugada syndrome (BrS) is a cardiac channelopathy predisposing patients to malignant ventricular arrhythmias and sudden cardiac death (SCD) in the absence of structural heart disease. The diagnosis requires documentation of a type 1 Brugada electrocardiographic pattern, which can be unmasked using sodium channel-blocking agents in symptomatic patients presenting with non-diagnostic baseline patterns. We report a case of a 24-year-old male patient with a history of unexplained syncope who exhibited a non-diagnostic type 2 Brugada pattern on a baseline electrocardiogram (ECG). Due to the local unavailability of standard intravenous antiarrhythmics, a pharmacological provocation test was conducted using a single 600 mg oral dose of propafenone. Under continuous cardiac monitoring, the patient safely developed a diagnostic type 1 "coved" electrocardiographic pattern starting at the third hour, confirming the diagnosis of BrS. The ECG returned to its baseline pattern eight hours after the initiation of the test, and no cardiovascular complications occurred. This case highlights the clinical utility and safety of oral propafenone as an effective alternative diagnostic challenge for unmasking BrS in resource-limited environments. Furthermore, it emphasizes the necessity of utilizing extended monitoring protocols due to the specific pharmacokinetic profile and delayed onset of action of oral agents.
- Aortic Valve (TAVR/TAVI)· Acta cardiologicaIntravascular imaging improves outcomes in left main PCI: insights from acute and chronic presentations.
- Aortic Valve (TAVR/TAVI)· Journal of nursing managementDevelopment and Initial Psychometric Validation of a Nurse-Assessed Discharge Readiness Scale for Patients With Coronary Heart Disease Following Percutaneous Coronary Intervention.
- Aortic Valve (TAVR/TAVI)· Journal of clinical and experimental dentistryElectromyography-guided percutaneous needle electrolysis for masticatory myofascial pain: A prospective clinical study.
- Mitral Valve (Repair & Replacement)· Annali italiani di chirurgiaMultidimensional Echocardiographic Parameters Predict Left Ventricular Functional Recovery After Coronary Artery Bypass Grafting.
- Mitral Valve (Repair & Replacement)· Medical Product OutsourcingFDA Flags Edwards TMVR Delivery System After Fatality - Medical Product Outsourcing
- Mitral Valve (Repair & Replacement)· IndexBoxTissue Mitral Valve Replacements Market Forecast to 2035, Driven by Aging Population and Transcatheter Innovation - IndexBox
